Management of Anemia in CKD with Low Hemoglobin and Normal Ferritin

Introduction to Anemia Management

For CKD patients with low hemoglobin and normal ferritin, the National Kidney Foundation recommends checking the transferrin saturation (TSAT) immediately—if TSAT is ≤30%, initiate erythropoiesis-stimulating agent (ESA) therapy with concurrent iron supplementation, as normal ferritin does not exclude functional iron deficiency in CKD 1

Normal ferritin does not mean adequate iron for erythropoiesis in CKD patients, according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 2, 3
The American Society of Nephrology suggests measuring TSAT alongside ferritin—TSAT reflects iron availability to bone marrow, while ferritin only reflects storage 4
In CKD, ferritin acts as an acute-phase reactant and can be falsely elevated by inflammation, masking true functional iron deficiency, as noted by the European Renal Association 4
Functional iron deficiency is defined as TSAT ≤20-30% despite ferritin >100 ng/mL, and this is extremely common in CKD, according to the National Institute of Diabetes and Digestive and Kidney Diseases 2, 5

If TSAT ≤30% and Ferritin ≤500 ng/mL, the American College of Physicians recommends starting with a trial of intravenous iron first, before initiating ESA therapy 1, 6, 7
IV iron is preferred over oral iron for CKD patients, particularly those approaching dialysis, as stated by the European Society of Nephrology 1, 6
Administer IV iron as a course (e.g., 500 mg initially, then 500 mg 4 weeks later), according to the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1
Check hemoglobin 2-4 weeks after completing the iron course to assess response, as recommended by the American Society of Nephrology 1, 7
59.4% of non-dialysis CKD patients respond to IV iron alone without ESA, with hemoglobin increases of 7-10 g/L, according to the National Kidney Foundation 3, 5

Monitor ferritin and TSAT at least every 3 months in all CKD patients on ESA therapy, as suggested by the European Renal Association 8, 6
If checking iron parameters after IV iron, wait 4-8 weeks before rechecking ferritin, as it becomes falsely elevated immediately post-infusion, according to the American College of Physicians 8

Occult gastrointestinal bleeding—particularly important in non-dialysis CKD with iron deficiency, as noted by the National Institute of Diabetes and Digestive and Kidney Diseases 4

Never assume normal ferritin means adequate iron in CKD—always check TSAT to assess functional iron availability, as recommended by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 2, 4
Do not withhold iron if TSAT is low despite normal ferritin—this represents functional iron deficiency requiring treatment, according to the European Society of Nephrology 2, 5
Avoid checking ferritin within 4 weeks of IV iron administration—results will be falsely elevated and misleading, as stated by the American Society of Nephrology 8

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends that patients with CKD stage 3 and functional iron deficiency should have a transferrin saturation (TSAT) of at least 20% for adequate iron availability, and a patient with a TSAT of 17% has inadequate iron available for red blood cell production 9
A hemoglobin level of 7.7 g/dL indicates severe anemia requiring urgent treatment, according to the Kidney International guideline 9

The American Society of Nephrology recommends administering IV iron as first-line therapy for CKD patients with functional iron deficiency, as oral iron is ineffective due to elevated hepcidin blocking intestinal absorption 9
IV iron bypasses the hepcidin-ferroportin block, allowing for more effective iron delivery to the bone marrow, as stated in the Kidney International guideline 10
IV iron achieves hemoglobin increases of 7-10 g/L compared to only 4-7 g/L with oral iron, according to the Kidney International Supplements guideline 11

The National Kidney Foundation recommends maintaining a TSAT of at least 20% and a ferritin level of at least 100 ng/mL during ongoing treatment for CKD stage 3 patients with functional iron deficiency, as stated in the Kidney International guideline 9, 11
Targeting a ferritin level of 400-600 ng/mL is superior to 100-200 ng/mL for achieving hemoglobin increases in non-dialysis CKD patients, according to the 2021 KDIGO conference data from the FIND-CKD trial 9, 12

The Kidney Disease: Improving Global Outcomes (KDIGO) guideline recommends retreating with IV iron if TSAT drops to 30% or less and ferritin drops to 500 ng/mL or less, and considering ESA therapy if hemoglobin remains less than 10 g/dL despite adequate iron repletion 9